San Francisco startup Structure Therapeutics is additionally engaged on an oral, the moment-each day GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June any time a mid-phase examine showed typical weight loss of all-around six% and it ideas to start out A different mid-stage demo to the end of the yr—that founde